Martina Kirchner

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9300799/publications.pdf

Version: 2024-02-01

40 papers	1,573 citations	361045 20 h-index	315357 38 g-index
40 all docs	40 docs citations	40 times ranked	2523 citing authors

#	Article	IF	Citations
1	Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma. Cancer Immunology, Immunotherapy, 2022, 71, 251-265.	2.0	22
2	Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 8.e11-8.e18.	0.8	8
3	Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine. Genes Chromosomes and Cancer, 2022, 61, 303-313.	1.5	15
4	The Different Immune Profiles of Normal Colonic Mucosa in Cancer-Free Lynch Syndrome Carriers and Lynch Syndrome Colorectal Cancer Patients. Gastroenterology, 2022, 162, 907-919.e10.	0.6	27
5	Histological and Molecular Plasticity of ALK-positive Non-Small-Cell Lung Cancer under Targeted Therapy - a Case Report. Journal of Physical Education and Sports Management, 2022, , mcs.a006156.	0.5	5
6	The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions. European Journal of Cancer, 2022, 170, 106-118.	1.3	15
7	Novel GATA6-FOXO1 fusions in a subset of epithelioid hemangioma. Modern Pathology, 2021, 34, 934-941.	2.9	27
8	Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592199650.	1.4	24
9	A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma. OncoImmunology, 2021, 10, 1860586.	2.1	40
10	Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report. Case Reports in Oncology, 2021, 14, 477-482.	0.3	8
11	De Novo Versus Secondary Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 640048.	1.3	4
12	Targeting rare and non-canonical driver variants in NSCLC â€“ An uncharted clinical field. Lung Cancer, 2021, 154, 131-141.	0.9	8
13	Testing NTRK testing: Wetâ€lab and in silico comparison of RNAâ€based targeted sequencing assays. Genes Chromosomes and Cancer, 2020, 59, 178-188.	1.5	52
14	<scp>miRNA</scp> profiling of biliary intraepithelial neoplasia reveals stepwise tumorigenesis in distal cholangiocarcinoma via the <scp>miR</scp>â€451a/<scp>ATF2</scp> axis. Journal of Pathology, 2020, 252, 239-251.	2.1	18
15	Frequent Molecular Subtype Switching and Gene Expression Alterations in Lung and Pleural Metastasis From Luminal Aâ€“Type Breast Cancer. JCO Precision Oncology, 2020, 4, 848-859.	1.5	7
16	Immunoâ€oncology gene expression profiling of formalinâ€fixed and paraffinâ€embedded clear cell renal cell carcinoma: Performance comparison of the <scp>NanoString nCounter</scp> technology with targeted <scp>RNA</scp> sequencing. Genes Chromosomes and Cancer, 2020, 59, 406-416.	1.5	10
17	Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary. International Journal of Cancer, 2020, 146, 3053-3064.	2.3	14
18	<scp>NTRK</scp> testing: First results of the <scp>QuiPâ€EQA</scp> scheme and a comprehensive map of <scp>NTRK</scp> fusion variants and their diagnostic coverage by targeted <scp>RNA</scp>â€based <scp>NGS</scp> assays. Genes Chromosomes and Cancer, 2020, 59, 445-453.	1.5	27

#	Article	IF	Citations
19	High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naÃ¯ve metastatic prostate cancer â€" Results from a prospective pilot study using a 37 gene panel. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 637.e17-637.e27.	0.8	12
20	Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors. Journal of Clinical Investigation, 2020, 130, 2488-2495.	3.9	23
21	RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples. Cancers, 2019, 11, 1309.	1.7	32
22	Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts. Journal of Thoracic Oncology, 2019, 14, 1935-1947.	0.5	69
23	Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival. Cancers, 2019, 11, 124.	1.7	36
24	Variant classification in precision oncology. International Journal of Cancer, 2019, 145, 2996-3010.	2.3	76
25	Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome. International Journal of Cancer, 2019, 145, 2963-2973.	2.3	24
26	Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and realâ€life analysis of three larger gene panels. International Journal of Cancer, 2019, 144, 2303-2312.	2.3	95
27	Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases. International Journal of Cancer, 2019, 145, 649-661.	2.3	85
28	Size matters: Dissecting key parameters for panelâ€based tumor mutational burden analysis. International Journal of Cancer, 2019, 144, 848-858.	2.3	131
29	Next generation sequencing of the cellular and liquid fraction of pancreatic cyst fluid supports discrimination of IPMN from pseudocysts and reveals cases with multiple mutated driver clones: First findings from the prospective ZYSTEUS biomarker study. Genes Chromosomes and Cancer, 2019, 58, 3-11.	1.5	14
30	Defining molecular risk in ALK+ NSCLC. Oncotarget, 2019, 10, 3093-3103.	0.8	35
31	Three molecular pathways model colorectal carcinogenesis in <scp>L</scp>ynch syndrome. International Journal of Cancer, 2018, 143, 139-150.	2.3	129
32	EML4â€ALK fusion variant V3 is a highâ€risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK⁺ nonâ€small cell lung cancer. International Journal of Cancer, 2018, 142, 2589-2598.	2.3	93
33	Targeted deep sequencing of effusion cytology samples is feasible, informs spatiotemporal tumor evolution, and has clinical and diagnostic utility. Genes Chromosomes and Cancer, 2018, 57, 70-79.	1.5	19
34	Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DKTK Molecularly Aided Stratification for Tumor Eradication Research Experience. JCO Precision Oncology, 2018, 2, 1-13.	1.5	20
35	Implementing tumor mutational burden (TMB) analysis in routine diagnosticsâ€"a primer for molecular pathologists and clinicians. Translational Lung Cancer Research, 2018, 7, 703-715.	1.3	152
36	Genetic profiling of melanoma in routine diagnostics: assay performance and molecular characteristics in a consecutive series of 274 cases. Pathology, 2018, 50, 703-710.	0.3	21

#	Article	IF	Citations
37	Precision oncology based on omics data: The NCT Heidelberg experience. International Journal of Cancer, 2017, 141, 877-886.	2.3	133
38	Synonymous EGFR variant p.Q787Q is neither prognostic nor predictive in patients with lung adenocarcinoma. Genes Chromosomes and Cancer, 2017, 56, 214-220.	1.5	8
39	Tubular, lactating, and ductal adenomas are devoid of MED12 Exon2 mutations, and ductal adenomas show recurrent mutations in GNAS and the PI3Kâ€“AKT pathway. Genes Chromosomes and Cancer, 2017, 56, 11-17.	1.5	27
40	Next-generation sequencing facilitates detection of the classic E13-A20 EML4-ALK fusion in an ALK-FISH/IHC inconclusive biopsy of a stage IV lung cancer patient: a case report. Diagnostic Pathology, 2016, 11, 133.	0.9	8